© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
November 14, 2022
The time of flare was significantly shorter in the placebo group compared to the baricitinib.
For safety, the proportions of patients with serious treatment-emergent adverse events in the second treatment period were similar between the treatment groups.
November 13, 2022
Two methods of identifying patients with axPsA, including an artificial intelligence approach, reported nearly identical outcomes with positive improvement of symptoms of axPsA.
Data from a phase 2 trial presented at ACR Convergence 2022 provides clinicians with insight into the effects of deucravacitinib, a TYK2 inhibitor, in patient populations with systemic lupus erythematosus.
The results show 88.1% of patients with rheumatoid arthritis in the study developed humoral immunogenicity.
A post hoc subgroup analysis compared TNFi-IR patients receiving upadacitinib 15 mg once daily in 3 Phase 3 clinical trials: SELECT-BEOYND, SELECT-CHOICE, and SELECT-COMPARE.
There were no significant safety issues in the group of patients treated with secukinumab for more than 3 years.
November 12, 2022
The results also show substantial medication substitution across prescription drug classes related to medical cannabis use.
Low levels of disease activity were achieved and increased throughout the study.
Adults in US with Vision Impairment Reported Lower Access to Health Care Services
PRA023 Showing Promise in Both Crohn’s Disease, Ulcerative Colitis
Why Health Care Was Unprepared for the 2022 RSV Surge